Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
Part of paid clinical trials in Huntington Beach, California.
- Sponsor
- EyePoint Pharmaceuticals, Inc.
- Study ID
- NCT05191706
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Cataract
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - 3 Years
- Healthy Volunteers
- Not accepted
Interventions
- Dexamethasone — DRUGsingle anterior chamber injection
- Prednisolone Acetate Ophthalmic — DRUGtopical administration four times a day for 28 days, followed by treatment taper
Study Details
A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
Key Dates
- Start date
- Jan 4, 2022
- Status verified
- Apr 2025
- Primary completion
- Jan 31, 2026
- Completion
- Feb 28, 2026
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: DEXYCU (dexamethasoneintraocular suspension) 9%A single 0.005-mL anterior chamber injection of DEXYCU (dexamethasoneintraocular suspension) 9%, equivalent to 517mcg dexamethasone.
- Active Comparator: Prednisolone acetate ophthalmic suspension (USP) 1%Active treatment control, prednisolone acetate ophthalmic suspension (USP) 1%, four times daily (QID) for 28days, followed by a treatment taper at the investigator's discretion.
Primary Outcome Measure
Grade of anterior chamber cells (ACC) [ Time Frame: Post-Operative Day 14 ]
Central Contacts
- Ramiro Ribeiro, MD, PhD833-393-7646
Locations (9)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| EyePoint Investigational Site | Huntington Beach | California | 92647 | - |
| EyePoint Investigational Site | Palo Alto | California | 94303 | - |
| EyePoint Investigative Site | Boston | Massachusetts | 02118 | - |
| EyePoint Investigational Site | Jackson | Mississippi | 39216 | - |
| EyePoint Investigational Site | Omaha | Nebraska | 68114 | - |
| EyePoint Investigational Site | Buffalo | New York | 14209 | - |
| EyePoint Investigative Site | New York | New York | 10032 | - |
| EyePoint Investigational Site | Rochester | New York | 14642 | - |
| EyePoint Investigational Site | Charleston | South Carolina | 29425 | - |
Find similar trials in Huntington Beach, CA
Related Studies
- Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital PopulationPHASE4 · Recruiting · University of California, San Francisco · San Francisco, California
- IC-8 Apthera IOL New Enrollment Post Approval StudyRecruiting · Bausch & Lomb Incorporated · Dothan, Alabama
- A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)PHASE3 · Recruiting · Melt Pharmaceuticals · Chico, California
- Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3%EARLY_PHASE1 · Recruiting · DHS Consulting · Westbury, New York